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Abstract
OBJECTIVE—All national organizations now recommend that women be screened for cervical 
cancer beginning at age 21 years, regardless of age of sexual initiation; however, studies have 
shown that providers continue to screen much earlier than recommended. Two federal cancer 
surveillance systems were used to quantify the burden of invasive cervical carcinoma among 
women younger than 40 years of age.
METHODS—We examined combined data from the National Program of Cancer Registries and 
the Surveillance, Epidemiology, and End Results Program covering 92% of the U.S. population. 
We calculated the age-adjusted incidence of cervical carcinoma among women younger than age 
40 years by age, race, ethnicity, and histology for the time period of 1999–2008.
RESULTS—For women younger than age 40 years, 78% of the cervical cancer cases were 
diagnosed in women aged 30–39, 21% were diagnosed in women 20–29 years of age, and 1% was 
diagnosed in women younger than age 20 years. There was an average of 3,063 cases of invasive 
cervical carcinomas annually from 1999 through 2008, with an average of 14 carcinomas per year 
(rate of 0.15 per 100,000 females) among those aged 15–19 years, and 125 carcinomas per year 
(rate of 1.4 per 100,000 females) among those aged 20–24 years.
CONCLUSION—Cervical cancer is very rare in young women. Widespread implementation of 
Pap testing over the past four decades has detected very few cases of cervical cancer in women 
younger than 25 while potentially causing harm with unnecessary follow-up interventions.
LEVEL OF EVIDENCE—III
Invasive cervical cancer is generally avoidable with appropriate screening and follow-up, 
which allow for detection and treatment of most lesions before invasion. Cervical cancer 
screening in women younger than 21 years is thought to be less effective than for older age 
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groups; thus, all national organizations have increased the age to begin screening regardless 
of onset of sexual activity.1–4 Cancers that do arise in young women have been suggested to 
be less detectable by traditional screening, or more aggressive and likely to arise during 
screening intervals.5
Cervical cancer is rare in young women, yet cytologic abnormalities found with Pap tests are 
very common because of the high prevalence of human papillomavirus, a sexually 
transmitted infection, in these women. An abnormal Pap test result can lead to being labeled 
with a sexually transmitted disease, anxiety, extended surveillance, and invasive 
procedures.6 When precancerous lesions are found, they often are treated with excisional 
procedures, which are associated with adverse pregnancy outcomes, including preterm 
delivery and low birth weight.7,8 Also, precancerous lesions diagnosed in young women 
usually spontaneously regress without treatment.9,10 However, studies have shown that 
providers are continuing to overscreen and overtreat this young population.11,12
Previous studies have analyzed national surveillance data for a majority of women in the 
United States with invasive cervical cancer without focusing on this younger 
population.13–17 With the recent recommendations from all national organizations to start 
screening at 21 years of age, more recent nationwide data could help reassure both clinicians 
and patients about safety in complying with these recommendations. The purpose of this 
study is to use nationwide surveillance data to examine invasive cervical cancer among 
women younger than 40 years of age in the United States, focusing on age, race or ethnicity, 
and histology.
MATERIALS AND METHODS
We used data from two federal cancer surveillance programs, the Centers for Disease 
Control and Prevention’s National Program of Cancer Registries and the National Cancer 
Institute’s Surveillance, Epidemiology, and End Results (SEER) Program to examine 
microscopically confirmed cervical carcinoma cases diagnosed from 1999 through 2008. 
These data cover 42 registries, which included 92% of the U.S. population for our years of 
study.18 The Centers for Disease Control and Prevention Institutional Review Board 
approved this study.
Rates were calculated in SEER*Stat, standardized to the 2000 United States Standard 
Population and expressed per 100,000 females. Age-adjusted rates of cervical carcinoma 
incidence are reported for 5-year age group (15–19, 20–24, 25–29, 30–34, and 35–39), 
combined race or Hispanic ethnicity, and histology. Patients classified as white and black 
are non-Hispanic; Hispanic patients include females from all race categories identified as 
Hispanic in the medical record or by use of an algorithm.19 The “all cases” category 
includes patients from all races and ethnicities. Histology was reported for carcinomas only, 
including squamous cell, glandular, and unspecified.
Age-specific incidence rates per 100,000 females are reported for 1999–2008 using the 
combined National Program of Cancer Registries and SEER data with 5-year age groups 
(15–19, 20–24, 25–29, 30–34, and 35–39). In addition, incidence rates are reported for 
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1973–2008 using SEER-only data to include a longer time of follow-up and age 20 years in 
the younger age category (0–20, 21–24, 25–29, 30–34, and 35–39) to reflect the guideline to 
start screening at age 21 years. Linear trends were examined using the weighted least-
squares method to determine annual percentage change among the time periods for each age 
category.
We also provide the number of Pap tests conducted per age group using data from the 
National Survey of Family Growth, which gathers information on female reproductive 
health as young as age 15 through 44 years.20 The survey asks information about whether a 
female had a Pap test in the past year. National Survey of Family Growth survey data from 
2006–2010 were weighted to the U.S. Census to provide national estimates of the number of 
annual Pap tests per 5-year age group. These estimates of Pap tests were then divided by the 
number of cancers per age group to allow for a proxy of the number of Pap tests that are 
conducted each year in relationship to the number of cancers diagnosed each year.
RESULTS
There was an average of 3,063 cases of invasive cervical carcinomas annually in our dataset 
from 1999 through 2008, with an incidence rate of 4.30 per 100,000 females (Table 1). For 
women younger than 40 years of age, 78% of the cervical cancer cases were diagnosed in 
women aged 30–39, 21% were diagnosed in women 20–29 years of age, and 1% was 
diagnosed in women younger than 20 years of age. Up to age 14 years, incidence rates were 
close to zero and were suppressed from the table because of low case counts. Rates 
increased steadily with age from 0.15 among those 15–19 years of age to 14.16 among 
women 35–39 years of age. Most cancers were squamous cell carcinomas; Hispanic females 
had the highest rate of squamous cell carcinomas of all groups studied. Black females had a 
significantly lower rate of glandular carcinomas than did other females.
Age-specific incidence rates of cervical carcinomas using National Program of Cancer 
Registries and SEER for 1999–2008 are shown in Figure 1. Of note is that over the course of 
the 10-year time period for those 0–19 years of age, the line could not be graphed because of 
small rates ranging from 0 to 0.06 and statistically significant (P<.05) decrease in incidence 
rates for all other age groups, with exception of those 34–39 years of age. Figure 2 provides 
the incidence rates using SEER data for 1973–2008. Similar findings are noted with the 
additional time and different age categories, again for the longer 36-year time span for 
females 0–20 years of age the rate was too small to graph and ranged from 0 to 0.15. A 
significant decrease (P<.05) in incidence is noted for all other age categories.
Table 2 provides information on the estimated number of Pap tests per cancer case as a 
crude proxy for the number of Pap tests needed to prevent a single cancer or screening 
efficiency. The number of cervical carcinomas in each age group was taken from Table 1. 
National Survey of Family Growth survey data were used to provide estimates of the 
number of Pap tests conducted annually for each age group. For females aged 15–19 years, 
an estimated 2,737,000 Pap tests were conducted and an average of 14 cases of cervical 
cancer were diagnosed annually, or nearly 200,000 screenings per cervical cancer. For 
women aged 20–24 years, an estimated 6,866,000 Pap tests were conducted and an average 
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of 125 cases of cervical cancer were diagnosed annually, or nearly 55,000 screenings per 
cervical cancer. As the number and rate of cancer cases increased with older age groups, the 
number of screenings per cancer detected declined, to a low of 4,921 Pap tests to detect one 
invasive cancer case among women aged 35–39 years.
DISCUSSION
Cervical cancer is not a very common cancer in the developed world and is even rarer in 
younger populations, with an average of only 14 carcinomas per year among those aged 15–
19 years, and 125 carcinomas per year among those aged 20–24 years. Precancerous lesions 
are frequently found among these age groups and are more likely to regress than at older 
ages.9,10 Based on the rarity of invasive disease and the potential harms of overscreening 
and treating this young population, national organizations have all moved toward a later 
starting age to screen for cervical cancer regardless of onset of sexual activity. However, 
studies have shown that providers are continuing to overscreen and overtreat this young 
population.11,12 With the introduction of the human papillomavirus vaccine, the prevalence 
of true cancer precursors is expected to decrease, thereby increasing the rate of false-positive 
results and unnecessary treatment.21
Studies have shown that cervical cancers arising among young females are often less 
detectable by traditional screening or are more aggressive and thus more likely to arise 
during screening intervals.5 In our study, histology varied according to age, with a larger 
proportion of noncarcinomas (defined as all histologies not included in International 
Classification of Disease codes 8010–8671 and 8940–8941) among the youngest age groups 
(data not shown). These non-carcinomas were often childhood cancers and would not be 
detected through screening. For the youngest age group, the most common tumor diagnosis 
was embryonal rhabdomyosarcoma.
Additionally, cervical cancer incidence varied by race or ethnicity and age. Overall, 
Hispanic females had the highest rates, although the magnitude of difference by race or 
ethnicity was lower among younger females than in previous studies examining all ages.14 
We found that black females had lower rates overall than white females, contrary to analyses 
including all ages. Black females also had the lowest rate of glandular carcinomas, 
consistent with other studies.13,14 These differences in race and ethnicity may be attributable 
to a combination of screening and follow-up rates as well as hormonal-based risk factors 
such as obesity, parity, and use of oral contraceptives.22,23
Although screening occurs less often in the youngest age group (15–19 years), an alarming 
2.7 million Pap tests still are conducted annually among this age group to detect an average 
of 14 cases of cancer that occur annually, or just less than 200,000 Pap tests per cervical 
cancer diagnosed (Table 2). Assuming a screening cost of approximately $60 (Pap test with 
office visit),24 the total cost of screening in this age group is estimated to be approximately 
$164,220,000, or approximately $11,646,800 per cancer case. For women aged 20–24, the 
cost is $3,285,200 per cancer case diagnosed. As age increases, the rate and number of 
cancers per year increase, and Pap testing becomes more effective, with women in their 30s 
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averaging approximately 5,000–6,000 Pap tests to detect one cancer case and an estimated 
cost per cancer case of approximately $300,000–$375,000.
We acknowledge that abnormal Pap test findings and subsequent follow-up ideally result in 
detecting precancerous lesions before they become cancer; thus, our calculation does not 
take into account cancers that may have been avoided. However, analyses examining the 
effect of screening on future cancer risk have found cervical cancer screening to be less 
effective for younger women.25,26 As found in our data, there was no change in the 
incidence of invasive cervical cancer across the 36-year and 10-year time periods for this 
younger population of females. The updated screening guidelines were based on a 
systematic evidence review that also provided rationale of the rarity of cervical cancer in 
young women.1 Additionally, a recent article by Habbema et al provides a cross-national 
case study of cervical cancer prevention efforts in both the United States and the 
Netherlands describing cancer-related outcomes to screening intensity.27 The authors found 
that even though women in the United States undergo more than three-times as much Pap 
testing as do women in the Netherlands, the decrease in cervical cancer mortality over the 
past five decades has been nearly identical and the rates of cancer comparable, noting that in 
the Netherlands women are not screened until age 30. A commentary to this article cites that 
the implication is clear: women in the United States typically undergo far too much 
screening (as well as too many false-positive results, colposcopies, and other downstream 
consequences).28
The goal of cervical cancer screening is to detect and treat preinvasive lesions that begin to 
peak in women in their late 20s.3 Colposcopy with biopsy is performed when evaluation of 
an abnormal Pap test result is needed.30 Recent data suggest that the risk for adverse effects 
from this procedure is not trivial, including pain, bleeding, and discharge.31 In addition, 
once precancers are identified they must be treated, and this includes potential harms both in 
the short-term (pain, discharge, bleeding)30 and in the long-term (increased risk of preterm 
delivery).7,8 Given these short-term and long-term risks and the high likelihood of 
regression among young women, available data suggest that screening women younger than 
21 years would result in more harms than benefits;3 therefore, all screening organizations 
now recommend against screening before age 21 years. Therefore, comprehensive 
vaccination in young women may be a better and more efficacious solution for preventing 
cancers in young women, because we can expect that it will be 70%–80% effective and 
without the harms of screening.
Data from two federal cancer surveillance programs were used in this analysis. The SEER 
data, which only cover 9% of the U.S. population, was used to give a longer time span (36 
years) to observe changes in cervical cancer rates. However, the combined data covering 
92% of the population were presented to give a more complete picture of the burden of the 
disease. Although population-based registries covering a majority of the U.S. population 
provide an excellent system to measure invasive cancers, they do not capture patient-level 
risk factors, including tobacco use, oral contraceptive use, or screening history, which could 
provide additional information for reasons for cervical cancer incidence by age or race or 
ethnicity.31 Additionally, race and ethnicity data come from medical records that may not be 
accurate for a small number of cases.32 However, our findings with regard to race and 
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ethnicity were similar to other studies.13,14 A final limitation to the collected data may be in 
the reproducibility of histologic classification of these cervical cancers and may affect the 
observed case distribution.33
Self-reported data (National Survey of Family Growth) were used to estimate the annual 
number of Pap tests because the United States does not currently have a national cervical 
cancer screening surveillance system. Additionally, the time period for current Pap tests 
(2006–2010) was not the same for the incidence data (1999–2008). However, we did 
examine the 2002 National Survey of Family Growth data and found a slight increase in the 
number of Pap tests, because this was before organizations updated their guidelines to 
suggest later initiation and longer screening intervals. Therefore, by using the current 
estimates of Pap test use, we are presenting a more conservative estimate.
As noted, invasive cervical cancer is extremely rare in females younger than 25 years of age. 
However, this age group has higher rates of transient human papillomavirus infection and 
regressive cervical abnormalities, the treatment of which possibly having harmful effects on 
future reproduction. Screening organizations have weighed the balance between potential 
harms associated with diagnosis and treatment with any potential benefits, and all agree that 
screening should not occur before age 21 years.
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Fig. 1. 
Recent trends in cervical carcinoma among females younger than 40 years of age from the 
National Program of Cancer Registries and Surveillance, Epidemiology, and End Results 
(SEER) program, 1999–2008. The estimated rates for ages 0–19 years are too close to zero 
to graph (rates range from 0 to 0.06). *The annual percent change is significantly different 
from zero (P<.05). Data from the Centers for Disease Control and Prevention’s National 
Program of Cancer Registries and National Cancer Institutes’ SEER Program covering 92% 
of the United States population for 1999–2008. Rates are per 100,000 and age-adjusted to 
the 2000 United States Standard Population (single ages to 84, Census P25–1130 standard).
Benard. Cervical Carcinoma Among Young Females. Obstet Gynecol 2012.
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Fig. 2. 
Trends in cervical carcinoma among females younger than 40 years of age from the National 
Program of Cancer Registries (National Program of Cancer Registries) and Surveillance, 
Epidemiology, and End Results (SEER) program, 1973–2008. The estimated rates for ages 
0–20 years are too close to zero to graph (rates range from 0 to 0.15). *The annual percent 
change is significantly different from zero (P<.05). Data from the Centers for Disease 
Control and Prevention’s National Program of Cancer Registries and National Cancer 
Institutes’ SEER Program covering 92% of the United States population for 1999–2008. 
Rates are per 100,000 and age-adjusted to the 2000 United States Standard Population 
(single ages to 84, Census P25–1130 standard).
Benard. Cervical Carcinoma Among Young Females. Obstet Gynecol 2012.
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Table 2
Comparison of Annual Cervical Carcinomas and the Estimated Number of Pap Tests by Age Group
Age (y)
Average Annual Count of Cervical 
Carcinomas*
Estimated No. of Pap Tests in the 
United States†
No. of Pap Tests Conducted for Every 
Cancer Diagnosed‡
15–19 14 2,737,000 194,113
20–24 125 6,866,000 54,753
25–29 519 7,492,000 14,444
30–34 1,035 6,496,000 6,275
35–39 1,369 6,736,000 4,921
*Average annual count from National Program of Cancer Registries and the Surveillance, Epidemiology, and End Results Program, 1999–2008.
†
Estimated number of Pap tests in the United States from the National Survey of Family Growth.
‡Number of Pap tests per cancer case indicates estimated number of Pap tests yearly divided by average annual count (numbers may differ because 
of rounding).
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